Ipamorelin
Ghrelin-receptor Agonist (research chemical)
Preclinical work characterizes ipamorelin as a selective GH secretagogue, but its one human clinical trial failed and there are no positive human outcome data; benefit is ungraded and safety unknown.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Limited evidence
Preclinical work characterizes ipamorelin as a selective GH secretagogue, but its one human clinical trial failed and there are no positive human outcome data; benefit is ungraded and safety unknown.
Early or sparse human evidence; conclusions remain uncertain.
Human Evidence
One human RCT (postoperative ileus) failed its primary endpoint; no positive outcome trials.
Mechanistic Plausibility
Selective ghrelin-receptor agonist that releases GH in animals.
Research Activity
Clinical development discontinued after the failed trial.
Safety Profile
No outcome-level human safety data for marketed use; unregulated product.
Consensus
Not approved; development halted.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
4/9
steps proven in humans
Partly established
3 steps not demonstrated: Large human RCTs · Clinical outcomes · Guideline / regulatory support
Guideline / regulatory support
Not shownNot approved.
Clinical outcomes
Not shownNo positive outcomes.
Large human RCTs
Not shownNone.
Small human outcome trials
ProvenOne Phase 2 trial — primary endpoint not met; program discontinued.
Human safety data
LimitedFrom the one Phase 2 trial.
Human biomarker / pharmacology
LimitedSome human exposure via the trial.
Animal
ProvenSelective GH release in animals.
Cell / in vitro
ProvenReceptor pharmacology.
Mechanistic plausibility
ProvenSelective ghrelin-receptor agonism.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
Preclinical GH release; a failed human trial
Ipamorelin is a selective GH secretagogue in preclinical models. Its only completed human trial — for postoperative ileus — did not meet its primary endpoint, and development was discontinued.
Clean secretagogue ≠ benefit
Being a 'clean' GH secretagogue is not the same as improving any outcome; the human record here is a failure, not a success.
Everything marketed
Whether it improves body composition, recovery, or any outcome (untested/negative), safe dose, and long-term safety are unknown.
Essentially none
Off-label / anecdotal use only; no active clinical program.
What would change the picture
A positive human outcome trial would be needed for any efficacy claim — none exists.
The biggest myth
“Ipamorelin improves body composition / recovery in people.”
No positive human outcome trials; the one completed human trial failed its endpoint.
Ask BioSignal
Still have a question about ipamorelin?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take ipamorelin
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
People search ipamorelin for muscle gain, recovery, and 'clean' GH release. Interest is not evidence: its one completed human trial failed, there is no evidence for the uses it is sold for, and it is prohibited in sport.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
Not Approved (development discontinued)
Availability
Unapproved research chemical
Sport (WADA)
Prohibited (GH secretagogue, S2.3) — confirm at publication
Known safety profile
Limited human data; class-typical GH-axis effects possible (water retention, glucose effects); no outcome-level safety characterization for marketed use.
Common issues
- Possible fluid retention
- Possible glucose effects
Use caution if
- Everyone (unstudied for marketed use)
- Cancer history
- Diabetes
- Pregnancy
Long-term unknowns
No long-term human safety data.
Limits of this evidence
Human evidence is a single failed trial plus preclinical pharmacology.
Full regulatory and sport detail
- Regulatory approval
- None (development discontinued after a failed trial).
- Approved indication
- None.
- Investigational
- Discontinued (postoperative ileus program).
- Research chemical
- Yes — sold as a research chemical.
- Compounding
- Not established as an approved compounding substance.
- Sport (WADA)
- GH secretagogues are prohibited (S2.3) — confirm at publication.
- Publication note
- Re-confirm regulatory and anti-doping status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 4 popular claims about ipamorelin.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 1
- Not established
- 3
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Ipamorelin selectively stimulates growth hormone.
Not established
- Ipamorelin improves body composition / recovery in people.
- Ipamorelin is a proven, effective therapy.
- It is safe / legal for athletes.
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Ipamorelin selectively stimulates growth hormone.SupportedLimited evidence
Preclinical pharmacology shows selective GH release with little effect on cortisol/prolactin.
Ipamorelin is a proven, effective therapy.Not establishedModerate confidence
Its clinical program was discontinued after a failed trial; it is not approved.
It is safe / legal for athletes.Not establishedModerate confidence
Unapproved research chemical; prohibited in sport (GH secretagogues, WADA S2).
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Post-bowel-resection (ileus)
- Intervention
- Ipamorelin IV
- Dose
- trial doses
- Duration
- perioperative
- Outcome
- GI recovery — primary endpoint NOT met (Beck 2014)
- Notes
- Program discontinued; no evidence-based dose for marketed uses.
Where scientists agree — and don’t
Agreed
- It is a selective GH secretagogue in preclinical models
Debated
- None substantive — clinical development ended after the failed trial
Unknown
- All body-composition/recovery outcomes and long-term human safety
What remains unknown
- Is there any positive human outcome (untested or negative)?
- What is a safe dose and the long-term safety?
- What is the product identity/purity in unregulated supply?
Questions people actually ask
Does ipamorelin work for muscle or recovery?
There is no evidence that it does. Its one completed human trial (for a different, gut-motility use) failed, and there are no positive human outcome trials for the muscle or recovery uses it is marketed for.
Is ipamorelin approved?
No — development was discontinued after a failed trial, it is not FDA-approved, and it is prohibited in sport.
Practical takeaways
- Ipamorelin's only completed human trial failed its endpoint; development was discontinued.
- There is no evidence for the body-composition/recovery uses it is sold for.
- 'Selective GH release' is a mechanism, not a proven benefit.
- It is unapproved, unregulated, and banned in sport.
- For muscle and recovery, rely on training, protein, and sleep — not an abandoned GH secretagogue.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
How we found out
1998 — Raun (Eur J Endocrinol)
Characterized as the first selective GH secretagogue (preclinical).
2014 — Beck (Int J Colorectal Dis)
Phase-2 human trial for postoperative ileus failed; development discontinued.
References
Verified sources. BioSignal does not print a citation it has not checked.
- 01
Ipamorelin, the first selective growth hormone secretagogue
Eur J Endocrinol 139(5):552-561 · 1998
- 02
Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Int J Colorectal Dis 29(12):1527-1534 · 2014
Version history
1.0
Initial review-hardened record (Experimental; Insufficient/Caution). Review cadence: Annual.
Continue exploring
Three places this record leads next.